FDA Issues Warning Letters to 30 Telehealth Companies Over Misleading Compounded GLP-1 RA Marketing

The US Food and Drug Administration (FDA) has issued 30 warning letters to telehealth companies for false or misleading marketing claims about compounded glucagon-like peptide-1 (GLP-1) receptor agonist products, the agency announced March 3, 2026. The letters target promotional materials on company websites that suggest compounded versions of GLP-1 RA therapies are equivalent to FDA-approved drugs, which may violate federal drug safety and marketing laws.¹

Regulators allege that the telehealth firms made unsubstantiated assertions about compounded GLP-1 RA products, including claims implying comparability to approved therapies, such as semaglutide- or tirzepatide-based medications, and about their safety or effectiveness. The warning letters mark a significant enforcement step under the Federal Food, Drug, and Cosmetic Act, with firms given 15 business days to correct violations.¹

This action is part of a broader regulatory crackdown on the online marketing and distribution of compounded weight-loss and diabetes drugs following earlier FDA statements regarding enforcement against non-FDA-approved GLP-1 RA treatments and misleading direct-to-consumer advertising. Separate industry reporting notes increased regulatory pressure on telehealth providers that have relied on compounded GLP-1 RA therapies as low-cost alternatives, affecting companies such as Hims & Hers Health amid scrutiny from both FDA and pharmaceutical manufacturers.^1,2

“It’s a new era of enforcement. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action,” FDA Commissioner Marty Makary, MD, MPH, said in a press release.¹ “Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to circumvent FDA’s approval process by mass-marketing compounded drugs."

The FDA’s warning letters focus specifically on misbranding and false advertising claims. Compounded drugs—medications prepared by licensed pharmacists to meet specific patient needs—are not evaluated by FDA for safety, efficacy, or quality, and claims that they are “equivalent” to approved GLP-1 RA therapies are potentially misleading to clinicians and patients.¹

Physicians prescribing weight-loss or antidiabetes therapies should be aware of the ongoing regulatory scrutiny around compounded GLP-1 RAs and the legal requirement that marketing must not imply comparability with FDA-approved agents. Further enforcement actions could include seizures, injunctions, or other legal remedies if corrective responses are insufficient.¹

References:

1. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. News release. US Food and Drug Administration. March 3, 2026. Accessed March 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
2. Halsey G. Hims & Hers Super Bowl Ad for Semaglutide "Nothing Short of Reckless," Says Partnership for Safe Medicines. Patient Care Online. February 7, 2025. Accessed March 3, 2026. https://www.patientcareonline.com/view/hims-hers-super-bowl-ad-for-semaglutide-nothing-short-of-reckless-says-partnership-for-safe-medicines